KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Q4 2025 value amounting to $8.8 million.

  • Alnylam Pharmaceuticals' Gains from Investment Securities rose 218416.08% to $8.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $21.2 million, marking a year-over-year increase of 12768.29%. This contributed to the annual value of $21.2 million for FY2025, which is 12768.29% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $8.8 million for Q4 2025, which was up 218416.08% from $3.8 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $9.8 million during Q1 2025, with a 5-year trough of -$1.3 million in Q2 2025.
  • Moreover, its 5-year median value for Gains from Investment Securities was $2.0 million (2024), whereas its average is $2.9 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Gains from Investment Securities skyrocketed by 313030.3% in 2022, and later crashed by 12220.12% in 2025.
  • Alnylam Pharmaceuticals' Gains from Investment Securities (Quarter) stood at -$165000.0 in 2021, then crashed by 130.91% to -$381000.0 in 2022, then surged by 1264.83% to $4.4 million in 2023, then tumbled by 109.53% to -$423000.0 in 2024, then soared by 2184.16% to $8.8 million in 2025.
  • Its Gains from Investment Securities was $8.8 million in Q4 2025, compared to $3.8 million in Q3 2025 and -$1.3 million in Q2 2025.